World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT01164787
Date of registration: 16/07/2010
Primary sponsor: Dr. Reddy's Laboratories Limited
Public title: Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions
Scientific title: An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and MavikĀ® 4 mg Tablets of Abbott Laboratories, in Healthy, Adult, Human Subjects Under Fasting Conditions
Date of first enrolment: March 2006
Target sample size: 52
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT01164787
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment  
Countries of recruitment
India
Contacts
Name:   Dr. Umesh Dhakate, M.B.B.S
Address: 
Telephone:
Email:
Affiliation:  Wellquest Clinical Research
Key inclusion & exclusion criteria

Inclusion Criteria:

- Healthy human subjects within the age range of 18 to 45 years

- Non-smokers since at least six months

- Willingness to provide written informed consent to participate in the study

- Body-mass index of = 18.5 kg/m2 and =24.9 kg/m2, with body weight not less than 50 kg

- Absence of significant disease or clinically significant abnormal laboratory values
on laboratory evaluations, medical history or physical examination during the
screening Normal 12-lead ECG or one with abnormality considered to be clinically
insignificant Normal chest X-ray PA view Comprehension of the nature and purpose of
the study and compliance with the requirement of the Protocol

- Female Subjects

- of child bearing potential practicing an acceptable method of birth control for
the duration of the study as judged by the investigator(s), such as condoms,
foams, jellies, diaphragm,intrauterine device (IUD), or abstinence, or

- postmenopausal for at least 1 year, or

- surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
hysterectomy has been performed on the subject

Exclusion Criteria:

- Personal/family history of allergy or hypersensitivity to Trandolapril or allied
drugs

- Past history of anaphylaxis or angioedema

- Any major illness in the past three months or any clinically significant ongoing
chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.

- Presence of any clinically significCint abnormal values during screening e.g.
significant abnormality of Liver Function Test (LFT), Renal (kidney) Function Test
(RFT), etc.

- Any cardiac, renal or liver impairment, any other organ or system impairment

- History of seizure or psychiatric disorders

- Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus

- Consumption of alcohol for more than two years, or consumption of more than three
alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing
and during the study [one drink is equal to one unit of alcohol [one glass wine, half
pint beer, and one measure (one ounce) of spirit).

- Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate)
within 48 hours before check-in of each period

- Use of any recreational drug or a history of drug addiction

- Participation in any clinical trial within the past 3 months

- Inaccessibility of veins in left and right arm

- Donation of blood (one unit or 350 mL) within 3 months prior to receiVing the first
dose of study medication

- Regular smoker who has a habit of smoking more than nine cigarettes per day and has
difficulty in abstaining from smoking from 48 hours before dosing and until the
completion of the study.

- Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC)
drugs within two weeks prior to receiving the first dose of study medication or
repeated use of drugs within the last four weeks

- An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to
receiving any medication and through out subject's participation in the study

- Consumption of grapefruit- containing food or beverages within 10 days prior to
receiving the first dose of study medication in both the periods

- Recent history of dehydration from diarrhoea, vomiting or any other reason within a
period of 24 hours prior to the study

- Female subjects who are pregnant or who are able (women with child bearing potential)
to become pregnant during the study will not be allowed to participate.



Age minimum: 18 Years
Age maximum: 45 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Healthy
Intervention(s)
Drug: Mavik
Drug: Trandolapril
Primary Outcome(s)
Bioequivalence is based on Cmax and AUC parameters. [Time Frame: 3 months]
Secondary Outcome(s)
Secondary ID(s)
CL-028-TRAN-2006
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history